Purchase Order 75D30121P12824
Award Date 9/23/21
Potential Completion Date 9/22/22
Potential Value $250K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Atlanta, GA 30329, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Walsh Healy Act
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Centers for Disease Control and Prevention has awarded a $300,000 firm fixed price purchase order to Nanocomposix, Inc. for lateral flow assay devices. The contract has no set-aside designation and runs through September 2023. Nanocomposix will deliver the requested lateral flow assay products to CDC under this contract. As a manufacturer of engineered nanoparticles located in San Diego, California, Nanocomposix has extensive experience providing lateral flow assays, gold nanoparticles,...
- <p>The U.S. Centers for Disease Control and Prevention (CDC) awarded a $110,025.00 firm-fixed-price purchase order to Nanocomposix, LLC, a for-profit limited liability company, to provide a NANOCOMPOSIX LATERAL FLOW ASSAY. The contract, which does not have a set-aside designation, has an ultimate completion date of September 30, 2024. The place of performance is San Diego, California.</p>
- This firm fixed price purchase order contract, awarded by the Centers for Disease Control and Prevention (CDC) to Nanocomposix, Inc., is for $150,000.00 and is for research and development under the Small Business Innovation Research (SBIR) program. The contract is not set aside for a specific business type. Nanocomposix is a small business that manufactures engineered nanoparticles and has previously performed prime contracts and subcontractor work for the National Institutes of Health, Food...
- This is a $1,500,000.00 Firm Fixed Price contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective of the contract is to develop cytomegalovirus (CMV) IgG and IgM lateral flow assays required to support a large-scale CMV vaccination trial. Nanocomposix has prior experience providing lateral flow assay devices,...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Nanocomposix, Inc. The $200,000.00 fixed-price contract is for the development of "Surface Enhanced Fluorescence Nanotags for Ultrasensitive Multiplexed Assay Systems." As a small business manufacturer of engineered nanoparticles, Nanocomposix has previously received prime federal contracts and...
- This is a $225,000.00 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Nanocomposix, Inc., a manufacturer of engineered nanoparticles. The contract is for the development of "TOPIC 59 DIAGNOSTICS TO ENABLE MALARIA AND NEGLECTED TROPICAL DISEASES". Nanocomposix has previously provided lateral flow assay devices, gold nanoparticles, and research and development...
- This is a $150,000.00 firm fixed-price definitive contract awarded by the U.S. Army Medical Command (MEDCOM) to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract has a period of performance ending on March 30, 2016. Nanocomposix has provided similar products and services to the Department of Health and Human Services and Department of Defense in the past, including lateral flow assay devices, gold nanoparticles, and research and development for...
- This SBIR Phase II contract was awarded by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The $997,267 cost-plus-fixed-fee contract is for the development of "bright, photostable surface enhanced fluorescent nanotags" to advance biomedical technologies. Nanocomposix has previously provided products and R&D services to NCI, FDA, CDC, and the...
- This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the Defense Health Agency (DHA) to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The $1,000,000.00 contract is for the development of a product or technology under the SBIR program. As a Phase II award, this indicates the company previously received a Phase I contract for preliminary research and development. The contract has a cost-plus-fixed-fee pricing type and a period of...
- This is a $1,000,000.00 Phase II SBIR contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The contract is for the rapid screening of individual cells using single cell mass spectrometry, supporting the NCI's biomedical research and development efforts. Nanocomposix has previously supported other federal agencies such as the Department of Defense...